Skip to content
Medical Health Aged Care

Aged Care Act must protect rights of people living with dementia

Dementia Australia 2 mins read

Following confirmation that the commencement date of the legislation will be changed Dementia Australia supports the concerns raised by COTA Australia and Older Persons Advocacy Network (OPAN) and reinforces the need for the timely introduction of the new Aged Care Act to protect and enforce the rights of older people.

 

COTA Australia and OPAN expressed concern that any delay to the introduction of the Aged Care Act should be avoided and swift action is needed.

 

Dementia Australia CEO Maree McCabe AM said older people deserve the robust, enforceable rights they were assured, without further delay.

 

“People living with dementia and carers want and deserve an Aged Care Act that genuinely protects their rights and ensures they receive quality care,” Ms McCabe said.

 

“A new rights-based Aged Care Act is fundamental to achieving the reforms recommended by the Royal Commission into Aged Care Quality and Safety three years ago and the Act is a vital framework for this change.

 

“While it is important to get the details right and incorporate feedback, older people must have a clear timeframe by which these new rights are enshrined in legislation.”

 

The new Aged Care Act was due to come into effect from 1 July 2024. This week the Federal Government announced they are considering refining the draft legislation before it is introduced to Parliament.

 

“If there is a delay in the rollout of the legislation, there needs to be robust and transparent consultation that underpins the parliamentary process and due consideration of how the Act will strengthen the delivery of quality dementia care,” Ms McCabe said.

 

“People impacted by dementia deserve to feel confident that the new Act will empower them and improve their experience of care and services.

 

“We welcome the ongoing progress made by the Albanese Government in addressing key recommendations of the Royal Commission and look forward to continuing to work with them to improve the health, care, lifestyle outcomes and experiences for people of all ages, living with all forms of dementia, and their families and carers.

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: Gabrielle Prabhu, Media & Communications Manager, 0447 253 583 or [email protected]   

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.